Completed × Has results × Stem Cell Transplantation × Clear all Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma
Phase 2 Completed
49 enrolled 15 charts
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
Phase 3 Completed
91 enrolled 24 charts
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
Phase 1 Completed
99 enrolled 11 charts
Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Phase 2 Completed
77 enrolled 17 charts
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Phase 2 Completed
62 enrolled 15 charts
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
Phase 1/2 Completed
34 enrolled 18 charts
Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1/2 Completed
19 enrolled 12 charts
A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative
Phase 1/2 Completed
27 enrolled 11 charts
Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation
Phase 1/2 Completed
62 enrolled 10 charts
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide
Phase 1/2 Completed
38 enrolled 17 charts
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Phase 1 Completed
55 enrolled 11 charts
CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma
Phase 1 Completed
48 enrolled 13 charts
High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors
Phase 2 Completed
64 enrolled 10 charts
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Phase 1 Completed
150 enrolled 9 charts
Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System
Phase 3 Completed
70 enrolled 12 charts
Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia.
Phase 1 Completed
18 enrolled 15 charts
Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
Phase 1/2 Completed
54 enrolled 18 charts
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
Phase 2 Completed
38 enrolled 11 charts
Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)
Phase 1/2 Completed
15 enrolled 10 charts
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Phase 2 Completed
66 enrolled 12 charts
Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia
Phase 2 Completed
23 enrolled 10 charts
Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701)
Phase 2 Completed
65 enrolled 21 charts
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Phase 2 Completed
68 enrolled 11 charts
Autologous Transplant for Multiple Myeloma
Phase 2/3 Completed
363 enrolled 25 charts
Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
Phase 2 Completed
64 enrolled 7 charts
Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers
Phase 2 Completed
62 enrolled 15 charts
Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)
Phase 2 Completed
24 enrolled 8 charts
Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation
Phase 2 Completed
30 enrolled 11 charts
Combined Haploidentical-Cord Blood Transplantation for Adults and Children
Phase NA Completed
87 enrolled 10 charts
Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma
Phase 2 Completed
33 enrolled 4 charts
Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies
Phase NA Completed
18 enrolled 7 charts
High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma
Phase 2 Completed
75 enrolled 11 charts
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
Phase 2 Completed
20 enrolled 9 charts
A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
Phase 3 Completed
205 enrolled 11 charts
Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies
Phase 2 Completed
73 enrolled 16 charts
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
Phase 2 Completed
176 enrolled 18 charts
High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease
Phase 2 Completed
81 enrolled 8 charts
Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies
Phase 1/2 Completed
50 enrolled 10 charts
Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation
Phase 2 Completed
120 enrolled 8 charts
Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease
Phase 2 Completed
52 enrolled 7 charts
Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.
Phase 1/2 Completed
177 enrolled 10 charts
Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia
Phase 2 Completed
21 enrolled 13 charts
Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 2 Completed
47 enrolled 10 charts
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Phase 2 Completed
100 enrolled 18 charts
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
Phase 1/2 Completed
92 enrolled 13 charts
Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies
Phase 2 Completed
68 enrolled 16 charts
Trial Of Double Umbilical Cord Blood Transplantation
Phase 2 Completed
20 enrolled 9 charts
S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Phase 2 Completed
147 enrolled 6 charts
Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia
Phase 2 Completed
56 enrolled 6 charts
Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL
Phase 2 Completed
20 enrolled 6 charts